AKT1 and glioma: Our study showed that treatment with ubenimex significantly reduced phosphorylated proteins involved in the Akt signaling pathways (p-Akt-ser437), while treatment with an Akt agonist compromised JQ1 efficacy, indicating that the Akt pathway plays an important role in ubenimex-improved JQ1 sensitivity in glioma.